Astellas Pharma revenue and financials
¥2,243.50Change from previous close: +0.38%Absolute change: +¥8.50
In the fiscal year ended March 2026, Astellas Pharma reported revenue of ¥2.14T (+11.87% year over year). Net income was ¥291.54B, a net margin of 13.6%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +11.87%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +474.49%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 13.6%
- FY to Mar 2025: 2.7%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 |
|---|---|---|---|---|
| Total revenue | 2,139,245 | 1,912,323 | 1,603,672 | 1,518,619 |
| Cost of revenue | 408,426 | 349,206 | 292,485 | 288,353 |
| Gross profit | 1,730,820 | 1,563,117 | 1,311,187 | 1,230,266 |
| Selling, general and administrative | 860,312 | 843,032 | 740,110 | 630,272 |
| Research and development | 314,827 | 327,651 | 294,187 | 276,128 |
| Operating income | 380,059 | 40,248 | 18,947 | 131,557 |
| EBIT | 390,659 | 48,914 | 36,974 | 141,140 |
| EBITDA | 585,253 | 248,046 | 194,814 | 246,878 |
| Interest expense | 14,072 | 17,677 | 12,005 | 8,779 |
| Pre-tax income | 376,587 | 31,237 | 24,969 | 132,361 |
| Income tax | 85,013 | -19,510 | 7,924 | 33,647 |
| Net income | 291,535 | 50,747 | 17,045 | 98,714 |
| Net income to common shareholders | 291,535 | 50,747 | 17,045 | 98,714 |
| Basic EPS | 162.77 | 28.35 | 9.51 | 54.24 |
| Diluted EPS | 162.22 | 28.24 | 9.47 | 54.09 |
| Average shares (basic) | 1,791 | 1,790 | 1,793 | 1,820 |
| Average shares (diluted) | 1,797 | 1,797 | 1,800 | 1,825 |